On July 29, GENFLEET-B fell 5.49% in regular trading, trading at 27.08 HKD/share with turnover of 16.95 million HKD, extending the previous session's decline.

On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its NDA accepted by the FDA, based on data from the pivotal Phase III RASolute 302 study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor currently conducting a Phase III registrational study in second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review ahead of GENFLEET-B poses sustained pressure on the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made a small reduction in its stake, contributing to weak market sentiment around the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)